1. In patients with resected stage III mismatch repair-deficient colon cancer, adjuvant atezolizumab plus standard chemotherapy improved disease-free survival compared ...
1. Neoadjuvant capecitabine-oxaliplatin chemotherapy did not improve three-year disease-free survival compared to upfront surgery in locally advanced colon cancer. 2. ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. In this randomized controlled trial, patients with resected stage III or high-risk stage II colon cancer who completed adjuvant ...
1. The 5-year disease-free survival was 80.3% in the exercise group and 73.9% in the education group, with an overall ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in the Lancet. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. An intermittent strategy with fluorouracil, leucovorin and irinotecan (FOLFIRI) plus panitumumab (PAN) following induction was feasible, showed reduced toxicity ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
